Roche delivered full-year results that matched analysts’ consensus, with group sales up 8% in Q4 driven by core brands such as Ocrevus and Tecentriq. CEO Thomas Schinecker highlighted a robust late-stage portfolio, noting that the company expects to file up to 19 new molecular entities by 2030. While sales growth held steady versus 2024, management warned that looming patent expirations on top sellers will require offset through internal R&D and selective acquisitions.

Roche reiterated its guidance for 2026, forecasting group sales growth in the mid single-digit range and adjusted EPS growth in the high single-digit range at constant currencies. This outlook remains unchanged from the prior year and assumes continued demand for immunology and oncology franchises, stable currency effects and a disciplined approach to cost management. The company emphasized that profit expansion is expected to outpace top-line growth, driven by operational efficiencies.

Genentech’s Phase II trial of CT-388, a dual GLP-1/GIP agonist, demonstrated a mean 22.5% weight reduction over 48 weeks in adults with obesity, on par with market incumbents. The study reported tolerability comparable to peer agents, with discontinuation rates within expected ranges. Roche plans to initiate a global Phase III program this quarter, aiming for primary completion by 2028. Positive readouts could unlock peak annual sales in the low-double-digit billions of dollars.

With the patent cliff approaching for key drugs, Roche’s near-term value hinges on late-stage assets such as CT-388 and investigational immuno-oncology candidates. Upcoming milestones include regulatory filings for two Phase III oncology trials and interim readouts from the cardiovascular pipeline in H2 2026. Investors will closely monitor trial progression timelines, potential M&A to bolster smaller therapy areas and management’s capital allocation between R&D and shareholder returns.